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Abstract: Background: Endocrine-disrupting chemicals (EDCs) are environmental chemicals/toxicants
that humans are exposed to, interfering with the action of multiple hormones. Bisphenol A (BPA) is
classified as an EDC with xenoestrogenic activity with potentially adverse effects in reproduction.
Currently, a significant knowledge gap remains regarding the complete spectrum of BPA-induced
effects on the human placenta. As such, the present study examined the effects of physiologically
relevant doses of BPA in vitro. Methods: qRT-PCR, Western blotting, immunofluorescence, ELISA,
microarray analyses, and bioinformatics have been employed to study the effects of BPA using
nonsyncytialised (non-ST) and syncytialised (ST) BeWo cells. Results: Treatment with 3 nM BPA led to
an increase in cell number and altered the phosphorylation status of p38, an effect mediated primarily
via the membrane-bound estrogen receptor (GPR30). Nonbiased microarray analysis identified 1195
and 477 genes that were differentially regulated in non-ST BeWo cells, whereas in ST BeWo cells, 309
and 158 genes had altered expression when treated with 3 and 10 nM, respectively. Enriched pathway
analyses in non-ST BeWo identified a leptin and insulin overlap (3 nM), methylation pathways (10 nM),
and differentiation of white and brown adipocytes (common). In the ST model, most significantly
enriched were the nuclear factor erythroid 2-related factor 2 (NRF2) pathway (3 nM) and mir-124
predicted interactions with cell cycle and differentiation (10 nM). Conclusion: Collectively, our data
offer a new insight regarding BPA effects at the placental level, and provide a potential link with
metabolic changes that can have an impact on the developing fetus.
Keywords: endocrine-disrupting chemicals; BPA; placenta; microarray
1. Introduction
Endocrine-disrupting chemicals (EDCs) are environmental chemicals (e.g., chemicals in
manufacturing and packaging materials) with the potential of disrupting the endocrine system
of humans and wildlife [1]. To date, among the hundreds of thousands of synthetic chemicals,
several hundred have been recognized as potentially having endocrine active properties [2]. EDCs are
widespread in the environment and can accumulate throughout the food chain, particularly since most
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of these lipophilic chemicals exhibit long half-lives [3]. A large body of research has indicated that in
humans, prolonged exposure to these chemicals can be associated with metabolic dysfunction, disorders
of the reproductive system, endocrine-related cancers, and neurodevelopmental diseases [4–11].
There are numerous groups of EDCs with very diverse uses, including plasticisers (e.g., bisphenol
A, BPA; and phthalates), pesticides (e.g., dichlorodiphenyltrichloroethane, DDT; and dieldrin), flame
retardants (e.g., polybrominated diphenyl ethers), and additives to consumer goods (e.g., parabens,
benzophenone, and synthetic musks such as galaxolide) [1]. BPA is an EDC which was first synthesised
in 1891 [12] and is now widely used in a variety of products (e.g., plastics, lining of aluminium cans,
and thermal receipts) [13], thus representing one of the most frequently detected emerging pollutants
in the environment [14]. Structurally, BPA consists of a phenolic and hydroxyl group bound to an
aromatic ring [BPA chemical formula: (CH3)2C(C6H4OH)2], which can bind to other compounds to
form polymers when used in manufacturing [14–16]. Certain conditions, such as heat and acidic or
basic environments, can cause leaching of BPA to its surroundings, leading to potential environmental
and human (predominantly oral) exposure to BPA [17]. This exposure appears to be linked to a number
of health risks, since BPA interacts with nuclear estrogen receptors (ERα and ERβ), membrane-bound
estrogen receptors (e.g., GPR30), and other receptors (e.g., human nuclear receptor estrogen-related
receptor γ) [18–20].
In humans, BPA has been detected in fetal and maternal plasma, as well as in amniotic and follicular
fluid, whilst deposits have also been found in placenta tissue [21]. Variable BPA concentrations have
been measured in these compartments in humans, ranging from 0.3 to 18.9 ng/mL and 0.2 to 9.2 ng/mL in
maternal and fetal plasma, respectively, as well as 1.0 to 104.9 ng/g in term placenta [21,22]. An increasing
body of evidence has shown that BPA has neurobehavioural, neurotoxic, and neuroendocrine effects.
The impact of BPA on neurodevelopment is not only linked to the effect on the placenta. There is
also evidence of a direct effect on the fetus, such as the HPA axis, thyroid receptors, and estrogen
receptors [9,23–25]. Moreover, BPA exposure in utero appears to be associated with implantation
problems, as well as preeclampsia, preterm births, and low birth weight [26–30]. Indeed, fetal
malformation was shown to be higher in offspring from mothers with higher levels of free circulating
BPA levels [31], whilst there is a potential association between BPA exposure and low birth weight of
infants, especially female [27]. Furthermore, high doses of BPA have been shown to affect the growth
of offspring in the first years of life [31,32]. Work conducted with concentrations found in human
tissues can also induce behavioural and neuronal alterations and cognitive deficits [31].
Understanding the effects of environmental chemicals during gestation is crucial, as normal fetal
development paves the way for subsequent normal development and growth [33]. We therefore
hypothesized that BPA can affect placentation and subsequently gestation by activating placental
estrogen receptors. Several studies have shown that BPA can exert proliferative effects acting
in a genomic and nongenomic manner in vitro and activate signalling cascades such as Akt and
MAPK [25,34–38].
In this study we have used placental cells (BeWo) as an in vitro model to study the effects of high
and low physiologically relevant concentrations of BPA. We have investigated initially the effect of
BPA in nonsyncytialised BeWos as a marker of 1st trimester trophoblasts by measuring changes in cell
number, activation of signalling cascades, and impact on gene expression using microarrays followed
by validation of these mRNA changes. We then expanded on our observations by assessing the effects
of BPA in a syncytialised model of BeWo cells, therefore resembling the endocrine-active component of
the human placenta. To the best of our knowledge, this is the first time that the effect of BPA in two
different states of placentation has been assessed.
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2. Materials and Methods
2.1. Cell Culture
BeWo (CCL-98™ ATCC®, Teddington, UK; is a human choriocarcinoma-derived cell line with
human trophoblastic qualities able to cellularly differentiate in vitro to syncytiotrophoblast cells using
8-bromo-cAMP or forskolin [39–41]. BeWo cells were grown in Ham F12 Medium supplemented
with 10% fetal bovine serum (FBS) (Gibco™, Thermo Fisher Scientific, Waltham, MA USA) and 0.1%
of penicillin/streptomycin. The cells were maintained in 75 cm2 nontreated culture flasks (Thermo
Fisher Scientific, Waltham, MA USA) under standard culture conditions in a humidified atmosphere
containing 5% CO2 at 37 ◦C.
2.2. Syncytialisation Using 8-Bromo-cAMP and Treatment with Bisphenol A (BPA)
BeWo cells were seeded onto 6-well plates and left to grow for 24 h with 2 mL of media and
treated with 50 µM 8-Bromo-cAMP (Tocris Bioscience™, Abington, UK) dissolved in sterile H2O for
72 h (estimated confluence at treatment ~70%). For hormone treatments, cells were plated on 6-well
plates and incubated at standard culture conditions. After 24 h, media was changed and cells were
treated for 24 h with 3 nM (a physiologically relevant concentration) BPA (Sigma-Aldrich, Gillingham,
UK) dissolved in ethanol, 10 nM BPA, 30 nM β-estradiol (E2; Sigma-Aldrich, Gillingham, UK), or pure
ethanol as a control. After 24 h, cells were processed for further experiments.
2.3. RNA Extraction, cDNA Synthesis, and Quantitative Reverse Transcription PCR (qRT-PCR)
Cells were grown in 6-well plates and treated as mentioned above. RNA was extracted using
the GenElute Mammalian Total RNA miniprep kit (Sigma-Aldrich, Gillingham, UK), following the
manufacturer’s instructions. Every sample was measured using the NanoDrop 2000C (Thermo
Fisher Scientific, Waltham, MA USA) spectrophotometer. Concentration was assessed by A260/A280
ratio, a range of 1.7–2.0 classified as acceptable. cDNA synthesis was performed using the
Precision NanoScript™ 2 Reverse Transcription Kit (Primerdesign, Camberley, UK) according to
the manufacturer’s instructions. PrecisionPlus mastermix premixed with SYBR green (Primerdesign,
Camberley, UK) and primers as described in Table 1 were used for qPCR. A QuantStudio™ 7 Flex
System Real-Time PCR System machine (Applied Biosystems, CA, USA) was used for the study.
Two-colour microarray-based gene expression using a low input Quick Amp labelling kit was
measured using Agilent Gene Expression SurePrint G3 Human GE v2 8x60k oligo microarrays using a
Sure Scan microarray scanner (Agilent, CA, USA). RNA was extracted from samples treated with 3 nM
and 10 nM BPA, as previously described, and 100 ng of RNA as input was used per sample. Scanning
and feature extraction were performed on a SureScan microarray scanner (Agilent, CA, USA) using
Feature Extraction software v12.0.
FunRich v3.1.3 [42] and Enrichr [43] were used for further analyses. FunRich analyses biological
processes, cellular components, protein domains and molecular functions, expression sites, biological
pathways, and transcription factors and provides a clinical synopsis of phenotypic terms using many
of the common genomic databases. To further analyse data, differentially expressed gene lists were
uploaded to the online bioinformatics application Enrichr. Enrichr uses databases, such as NCI Nature
and Go Molecular Function, to assess gene enrichment in terms of molecular function, biological
processes, biological pathways, transcription factors, diseases, and other gene enrichment groups.
2.4. Western Blotting
Protein lysates were extracted from transfected and control BeWo cells. Proteins were first
separated by a 10% v/v SDS-PAGE and then the separated proteins were electrophoretically transferred
onto a nitrocellulose membrane (Thermo Scientific, Waltham, MA USA). After wet transfer, membranes
were blocked in 5% milk powder in 1x TBS Tween for one hour. Membranes were treated with primary
antibodies for AKT, p38, ERK1/2 (total and phospho), and GAPDH (Cell Signaling Technology®, MA,
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USA) in 5% BSA at a dilution of 1:1000 and incubated at 4 °C overnight. Membranes were washed
3 times for 15 min with 1x TBS Tween. Secondary anti-rabbit HRP-conjugated secondary antibody
(Cell Signaling Technology®, MA, USA) diluted in 5% BSA at a dilution of 1:2000 was added, and
membranes were incubated at room temperature for 1 h. Membranes were washed 3 times for 15 min
with 1x TBS Tween followed by developing, as previously described [44].
Table 1. List of primers used for qRT-PCR.
Gene Sequence
CAV1
F: 5′ACCCACTCTTTGAAGCTGTTG3′
R: 5′GAACTTGAAATTGGCACCAGG3′
Leptin F: 5
′CCTGACTGGTGCTATAGGCTGGA3′
R: 5′GTGAGTGCGGTTTGACCACTG3′
hPLAC8
F: 5′GGGTGTCAAGTTGCAGCTGAT3′
R: 5′TAGATCCAGGGATGCCATATCG3′
Syncytin 2 F: 5
′AGCAGCCGTAGTCCTTCAAA3′
R: 5′AGGGGAAGAACCCAAGAGAA3′
ERα
F: 5′GCCCTCCCTCCCTGAAC3′
R: 5′TCAACTACCATTTACCCTCATC3′
ERβ F: 5
′TCCTCCCAGCAGCAATCC3′
R: 5′CCAGCAGCAGGTCATACAC3′
GPR30
F: 5′GTTCCTCTCGTGCCTCTAC3′
R: 5′ACCGCCAGGTTGATGAAG3′
TOP1
F: 5′CCTTCCCTCTCTCCCATTTC3′
R: 5′AGCCACGACTGCTTCAAGTT3′
CAV1: Caveolin 1, hPLAC8: Placenta-specific gene 8 protein, ERα: Estrogen receptor-alpha, ERβ: Estrogen
receptor-beta, GPR30: membrane-bound estrogen receptor, TOP1: DNA topoisomerase I.2.4. Microarray.
2.5. Immunofluorescence
BeWo cells were grown and seeded at a specific density in a 6-well plate that contained coverslips
as above. After 24 h, media was changed to 0.5% FBS starved media and left to incubate for one hour.
Then, cells were treated with BPA (3 nM, 10 nM) and E2 (30 nM) for 24 h, 1 h, 30 min, 15 min, and 5 min.
Cells were fixed with cold 4% PFA as mentioned above. Cells were stained as previously mentioned
using appropriate antibodies for E-Cadherin (Cell Signaling Technology®, MA, USA), ERs, and GPR30
(Santa Cruz, Dallas, TX, USA) [44].
2.6. Statistical Analysis
Student’s t-test or ANOVA tests were performed on data of equal variance in order to compare
data sets. In unequal variance data, the Mann–Whitney U test was used to determine significance.
Values were significant at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
3. Results
3.1. BPA Effects on Phosphorylation of Key Kinases and Cell Number
In order to assess the short-term effect of BPA on undifferentiated (i.e., nonsyncytialised) BeWo
cells, these were treated with BPA at physiologically relevant concentrations of 3 nM and 10 nM for
5 to 60 min and phosphorylation levels of p38, ERK1/2, and AKT were measured, since they are
known modulators of trophoblast biology. After 60 min of treatment (Figure 1A), phospho-p38 levels
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were significantly increased in both 3 nM (p < 0.05) and 10 nM treated cells (p < 0.01). A statistically
significant increase by 2-fold in the phosphorylation status of AKT was observed after 60 min following
a 10 nM treatment with BPA (p < 0.05; Figure 1B). Phospho-ERK1/2 expression remained unaltered at
all tested time points after exposure to both 3 nM or 10 nM BPA (Figure 1C).
BPA at 3 nM for 24 h was also able to significantly increase cell numbers (p < 0.05; Figure 1D).
We dissected this response further by using the PI3K-inhibitor LY294002 and the MAPK-inhibitor
UO126, as well as the estrogen receptor antagonist ICI 182,780 (ERα and ERβ inhibitor) and the GPR30
inhibitor G15 in the presence of BPA. When treating BeWo cells with ER antagonists, there was a
significant decrease in cell numbers over 24 h when cells were treated with G15 and a moderate—but
not significant—decrease when treated with the ERα antagonist ICI 182,780 (Figure 1E). There was a
significant decrease in cell numbers over 24 h when treated with 3 nM BPA in the presence of LY294002
(p < 0.001; Figure 1E), and just short of significance for the U0126 (p = 0.05; Figure 1E).
3.2. Gene Microarray Analyses Assessing the Effects of BPA in Nonsyncytialised BeWo Cells
BeWo cells were treated with 3 nM or 10 nM BPA for 24 h in order to assess effects of BPA on
transcription and cell functions and pathways on nonsyncytialised BeWo cells. Genes were classified
from highest to lowest p-value and highest to lowest fold-change compared to untreated controls
and analysed using the FunRich bioinformatics analysis software. Microarray analysis identified
1195 genes that were differentially regulated in 3 nM treated nonsyncytialised BeWo cells, whereas
the 10 nM treated cells only showed differential regulation of 477 genes. A total of 194 genes were
commonly regulated by both concentrations.
Of the top upregulated genes (according to p-values) in 3 nM treated nonsyncytialised BeWo cells,
the most significantly upregulated gene was the cytoplasmatic polyadenylation element-binding protein
1 (CPEB1), which is vital for cell cycle progression, particularly prophase entry. Other coregulated genes
included Rap guanine nucleotide exchange factor (RAPGEF1), Myosin Light Chain 3 (MYL3), Caveolin-1
(CAV1), Calsyntenin-3 (CLSTN3), Hydroxycarboxylic acid receptor 3 (HCAR3), Serpin B9 (SERPINB9),
Alanine–glyoxylate aminotransferase 2 (AGXT2), Transmembrane protein 45B (TMEM45B), and
Eukaryotic translation initiation factor 4E type 2 (EIF4E2). Similarly, amongst the most upregulated
genes following 10 nM BPA treatment were CAV1, followed by MYL3, Cerebellin-1 (CBLN1), Ankyrin-3
(ANK3), Thiopurine S-methyltransferase (TPMT), Leptin (LEP), Hyaluronan and proteoglycan link
protein 3 (HAPLN3), Sperm flagellar 1 (SPEF1), Placenta-specific 8 (PLAC8), and EIF4E2.
3.3. Validation and Enrichment Analyses on Gene Microarrays
In order to validate the outcome of the microarray analyses, certain upregulated genes were
selected and transcription levels were assessed using qRT-PCR. The genes chosen for validation
were CAV1, Leptin, and PLAC8, which were chosen on the basis of possible relation to placental
function or cell function. These three genes were significantly upregulated in both 3 nM and 10 nM
BPA-treated undifferentiated (nonsyncytialised) BeWo cells. There was a relative increase in leptin gene
expression when compared to controls after 10 nM BPA treatment (Figure 2A). This is in accordance
with the 2.22-fold change difference between untreated BeWo cells and 10 nM BPA-treated cells seen in
microarray analysis. Similarly, there was a relative increase in PLAC8 gene expression when compared
to controls. This was also in accordance with the 1.75-fold change difference found between untreated
BeWo cells and 3 nM BPA-treated BeWo cells, as well as untreated BeWo cells and 10 nM BPA-treated
BeWo cells (Figure 2B). Finally, CAV1 gene expression significantly increased in 10 nM BPA-treated
BeWo cells compared to controls (p < 0.01), whilst an increase that did not reach statistical significance
was also noted in BeWo cells after 3 nM BPA treatment (Figure 2C). This was also in accordance with
the 2.35-fold change difference found in microarray analysis between untreated BeWo cells and 3 nM
BPA-treated BeWo cells.
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(BPA) treatmen (3 M and 10 nM). Treatment of BeWo cell t 3 nM and 10 nM BPA s gnificantly
increased th expr ssion of p-p38 after 60 min (* p < 0.05 0.01 compared to no supplement
(NS)) (A). Treatment of BeWo cells with 10 nM BPA significa tl i creased the expressi n of p-AKT
after 60 min (* p < 0.05 compared to NS) (B). Both protein expression of the housekeeping gene GAPDH
and of total p38 remained unchanged; (C). There was no difference in the phosphorylation status of
ERK1/2 when cells were treated with BPA for 60 min; (D). Changes in BeWo cell number treated with
3 nM BPA, 10 nM BPA, and 30 nM estradiol (E2). The 3 nM BPA treatment significantly increased cell
number compared to controls (p < 0.05), while there was a notable, but not significant, increase in
number when cells were treated with 10 nM BPA or 30 nM E2; (E). Changes in the number of BeWo
cells treated with 3 nM BPA and/or estrogen receptor (ER) antagonists (i.e., ICI 182,780 (ICI): ERα and
ERβ inhibitor, G15: GPR30 inhibitor). Cell number of BPA-treated cells was significantly decreased
when treated with G15 (p < 0.05). There was also a significant decrease in cell number when cells
were treated with LY294002 (LY), as well as for the treatment with BPA + LY294002 when compared to
controls and treatment with only BPA (*** p < 0.001 compared to control). There was a decrease in cell
number when cells were treated with U0126 or BPA + U0126 when compared to treatment with only
BPA just short of significance (p = 0.05).
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BeWo cells found in microarray anal sis; (B). There was a notable increase in l -s ecific 8
(PLAC8) gene expression when compared to controls after 3 nM and 10 nM BPA treat e t. in
accordance with the fold-change difference found between untreated BeWo cells and 3 nM BPA-treated
BeWo cells (1.75), as well as between untr ated BeWo c lls and 10 nM BPA-treated B Wo cells (2.14);
(C). There was a significant increase in Caveolin-1 (CAV1) when comparing untreated BeWo cells to
10 nM BPA-treated BeWo cells (p < 0.01). This is in accordance with the fold-change difference found
between untreated BeWo cells and 3 nM BPA-treated BeWo cells (2.35), as well as untreated BeWo cells
and 10 nM BPA-treated BeWo cells (3.55).
Enrichment analyses using Enric r ( i i at ays 2019 Human database) revealed that the
biological pathways ost significantly associated with differentially expressed genes in 3 nM and
10 nM BPA-treated BeWo cells are associated with insulin resistance (Table 2) and differentiation of
white and brown adipocyte (Table 3), respectively.
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Table 2. Top 10 pathways associated with differentially expressed genes after 3 nM bisphenol A (BPA)
treatment of BeWo cells using the WikiPathways 2019 Human database (Enrichr). The most significantly
regulated pathway is leptin/insulin overlap.
Index Biological Pathway p Value Input Genes
1 Leptin/insulin overlap 0.0016
suppressor of cytokine signaling 3 (SOCS3),
suppressor of cytokine signaling 1 (SOCS1), leptin
(LEP), insulin receptor substrate 2 (IRS2)
2 Differentiation of whiteand brown adipocyte 0.0098
PLAC8-like 1 (PLAC8), LEP, SMAD family member 9
(SMAD9), zinc finger protein 423 (ZNF423), PPARG
coactivator 1 beta (PPARGC1B)
3 Kit receptor signallingpathway 0.0136
ribosomal protein S6 kinase, 90 kDa, polypeptide 3
(RPS6KA3), (mitogen-activated protein kinase 8)
MAPK8, SOCS1, ribosomal protein S6 kinase B1
(RPS6KB1), SHC (Src homology 2 domain containing)
transforming protein 1 (SHC1), inositol
polyphosphate-5-phosphatase D (INPP5D), FYN
proto-oncogene, Src family tyrosine kinase (FYN),
microtubule-associated protein tau (MAPT)
4 Integrin-mediated celladhesion 0.0205
vasodilator-stimulated phosphoprotein (VASP), G
protein-coupled receptor kinase interacting ArfGAP 2
(GIT2), (SHC1), Rho-associated, coiled-coil containing
protein kinase 2 (ROCK2), CAV1, integrin, alpha 1
(ITGA1), integrin, alpha X (complement component 3
receptor 4 subunit) (ITGAX), Rap guanine nucleotide
exchange factor (GEF) 1 (RAPGEF1), p21 protein
(Cdc42/Rac)-activated kinase 6 (PAK6), integrin,
alpha 6 (ITGA6), FYN
5 Prolactin signallingpathway 0.0211
SOCS3, MAPK8, SOCS1, RPS6KB1, SHC1, erb-b2
receptor tyrosine kinase 2 (ERBB2), IRS2, FYN
6 Leptin signallingpathway 0.0211
SOCS3, MAPK8, RPS6KB1, SOCS1, SHC1, ROCK2,
LEP, ERBB2, BCL2-associated X protein (BAX), FYN
7 IL-2 signalling pathway 0.0244 SOCS3, RPS6KB1, SHC1, FYN, N-myc (and STAT)interactor (NMI), MAPT
8
Angiopoietin-like
protein 8 regulatory
pathway
0.0265
SHC1, solute carrier family 2 (facilitated glucose
transporter), member 1 (SLC2A1), protein kinase,
AMP-activated, gamma 1 non-catalytic subunit
(PRKAG1), phosphoinositide-3-kinase, regulatory
subunit 3 (gamma) (PIK3R3), IRS2, RPS6KA3,
MAPK8, sestrin 3 (SESN3), RPS6KB1, RAPGEF1,
mitogen-activated protein kinase kinase kinase 6
(MAP3K6), son of sevenless homolog 2 (SOS2),
mitogen-activated protein kinase kinase kinase 5
(MAP3K5)
9 Insulin signalling 0.0268
syntaxin binding protein 4 (STXBP4), SHC1, SLC2A1,
PIK3R3, RPS6KA3, SOCS3, MAPK8, SOCS1,
RPS6KB1, RAPGEF1, tribbles pseudokinase 3 (TRIB3),
MAP3K6, SOS2, MAP3K5
10 Focal adhesion 0.0403
vasodilator-stimulated phosphoprotein (VASP), von
Willebrand factor (VWF), SHC1, ROCK2, laminin,
beta 2 (laminin S) (LAMB2), CAV1, ITGA1, PIK3R3,
Rho GTPase activating protein 5 (ARHGAP5),
myosin light chain kinase (MYLK), MAPK8, ERBB2,
RAPGEF1, p21 protein (Cdc42/Rac)-activated kinase
6 (PAK6), filamin B, beta (FLNB), ITGA6, FYN
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Table 3. Top 10 significant biological pathways associated with differentially expressed genes after
10 nM bisphenol A (BPA) treatment of BeWo cells using the WikiPathways 2019 Human database
(Enrichr). The most significantly regulated pathway is differentiation of white and brown adipocyte.
Index Term p Value Input Genes
1 Differentiation of whiteand brown adipocyte 0.002
PLAC8, SMAD family member 1 (SMAD1), LEP,
PPARGC1B
2 Methylation pathways 0.015 nicotinamide N-methyltransferase (NNMT),thiopurine S-methyltransferase (TPMT)
3
Mechanoregulation and
pathology of YAP/TAZ
via Hippo and
non-Hippo mechanisms
0.019
integrin, beta 4 (ITGB4), integrin, beta 3 (ITGB3),
macrophage stimulating 1 (MST1), actin, gamma 2
(ACTG2)
4
Photodynamic
therapy-induced
unfolded protein
response
0.021 DNA-damage-inducible transcript 3 (DDIT3), TRIB3,activating transcription factor 3 (ATF3)
5 Alanine and aspartatemetabolism 0.027
alanine-glyoxylate aminotransferase (AGXT),
argininosuccinate synthase 1 (ASS1)
6 Mitochondrial geneexpression WP391 0.064
GA binding protein transcription factor, beta subunit
1(GABPB1), PPARGC1B
7 Hypertrophy model 0.070 ATF3, heparin-binding EGF-like growth factor(HBEGF)
8 Complement activation 0.083 Complement C 3 (C3), C15
9 Exercise-inducedcircadian regulation 0.087
DAZ associated protein 2 (DAZAP2), cryptochrome
circadian clock 2 (CRY2)
(10 NRF2 pathway 0.101
ATP-binding cassette, sub-family C (CFTR/MRP),
member 3 (ABCC3), early growth response 1 (EGR1),
solute carrier family 6 member 9 (SLC6A9),
glutathione S-transferase alpha 4 (GSTA4), solute
carrier family 39 member 7 SLC39A7, HBEGF
The most enriched biological processes were cell fate commitment and skeletal development for
3 nM BPA (Figure 3A,B). The two genes involved in cell fate commitment are CDCA4 and CASZ1,
which appear to have two distinct clusters of genes that are associated with (Figure 3C, Supplementary
Table S1).
The most enriched biological processes were microtubule-based process, cell adhesion, and
pyrimidine salvage for 10 nM BPA (Figure 4A,B). The four genes involved in cell adhesion are PCDH1,
ITGB4, FAT3, and MGAT5B, which form an extensive network of genes associated with (Figure 4C,
Supplementary Table S2).
3.4. Validation of the in Vitro Syncytialisation Model of BeWo Cells
BeWo cells were treated with 8-bromo-cAMP (8-Br-cAMP) for 72 h to fuse and form syncytia.
E-cadherin, a cell membrane-bound protein which mediates cell-to-cell interaction, was visualized
through immunofluorescence as a marker of cell membrane borders (marker of cell fusion).
As trophoblasts fuse to become syncytiotrophoblasts, giant cells containing multiple nuclei and one
surrounding cell membrane develop, whilst E-cadherin staining around individual cells disappears [45].
Here, we have shown that BeWo cells lose E-cadherin after treatment with 8-Br-cAMP when compared
to untreated cells. There is a loss of cell membrane and a certain degree of cell fusion to form large,
amorphous, multinucleated syncytia which represent the more endocrine active component of the
placenta (Figure 5A).
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(CLN8). (C) Network annotation of genes involved in cell fate commitment (Genemania).
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bottom row have been treated with 8-Br-cAMP for 72 h, while cells depicted in the top row have not 
(controls). As BeWo cells treated with 8-Br-cAMP fuse to become syncytia (amorphous and 
multinucleated cells), cell walls break down and lose E-Cadherin. (B) Secretion of estradiol (E2) and 
β-human chorionic gonadotropin (β-hCG) in conditioned media of nonsyncytialised and 
syncytialised BeWo cells grown for 24 h. Expression of both β-hCG and E2 was significantly 
upregulated in syncytialised BeWo cells (p = 0.0108 and p = 0.0042, respectively) compared to 
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Figure 5. (A) Immunofluorescent staini g of E-Ca ri ( arker of cell fusio ) in BeWo cells treated
with 8-bromo-cAMP (8-Br-cAMP) in order to sync tialise. Green: E-Cadherin; blue: DAPI nuclear stain
(a blue fluorescent dy used to det ct nucl i i fluorescenc microscopy). Cells depicted in the bottom
row have been treated with 8-Br-cAMP for 72 h, while cells depicted in the top row have not (controls).
As BeWo cells treated with 8-Br-cAMP fuse to become syncytia (amorphous and multinucleated cells),
cell walls break down and lose E-Cadherin. (B) Secretion of estradiol (E2) and β-human chorionic
gonadotropin (β-hCG) in conditioned media of nonsyncytialised and syncytialised BeWo cells grown
for 24 h. Expression of both β-hCG and E2 was significantly upregulated in syncytialised BeWo cells
(p = 0.0108 and p = 0.0042, respectively) compared to nonsyncytialised BeWo cells. (C) Expression of
syncytin-2 (a marker of syncytialisation) in nonsyncytialised and syncytialised BeWo cells, showing
a more than 2-fold increase in syncytin-2 in the latter (relative quantities are levels of the gene of
interest in relation to quantities of housekeeping gene TOP1). (D) All three estrogen receptors (ERα,
ERβ, and GPR30) were also present in syncytialised BeWo cells compared to nonsyncytialised BeWo
cells. (Insert in D). Immunostaining of syncytialised BeWo cells for estrogen receptors; merged images.
Green: receptor; blue: DAPI nuclear stain. ERα and ERβ show a more nuclear staining pattern, whereas
GPR30 staining is more focused around the cell membrane.
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As the syncytiotrophoblast exhibits considerable hormone-secreting properties, we measured the
levels of two placental hormones, β-human chorionic gonadotrophin (β-hCG) and E2, in conditioned
media of nonsyncytialised and syncytialised BeWo cells cultured for 24 h. Both hormones were
significantly increased (β-hCG, p = 0.0108; E2, p = 0.004) following syncytialisation of BeWo cells with
8-Br-cAMP treatment (Figure 5B). Moreover, Syncytin-2 (a marker of syncytialisation) showed relative
upregulation (more than 2-fold) in 8-Br-cAMP-treated BeWo cells compared to untreated BeWo cells
(Figure 5C). All three estrogen receptors (ERα, ERβ, and GPR30) were also detected in syncytialised
BeWo cells at mRNA (Figure 5D) and protein level (Figure 5E).
3.5. Gene Microarray Analyses Assessing the in Vitro Effects of BPA in Syncytialised BeWo Cells
Syncytialised BeWo cells were analysed separately in order to assess significantly differentially
regulated genes and their functions, as well as involvement in cell signalling pathways. Overall, in
syncytialised BeWo cells treated with 3 nM BPA, 309 genes were differentially regulated, whilst in those
treated with 10 nM BPA, 158 genes were differentially regulated. Only one gene was commonly shared
between the two BPA treatments, that is, Fatty-Acid-Binding Protein 5 (FABP5). The most significantly
upregulated genes in syncytialised BeWo cells following 3 nM BPA treatment were: Growth Hormone
Releasing Hormone (GHRH), followed by UDP-glucuronosyltransferase 2B10 (UGT2B10), Carbonic
anhydrase-related protein 11 (CA11), Natural resistance-associated macrophage protein 1 (SLC11A1),
Rab proteins geranylgeranyltransferase component A1 (CHM), OTU domain-containing protein 7A
(OTUD7A), Envoplakin-like protein (EVPLL), Envoplakin-like protein (SLFNL1), Excitatory amino
acid transporter 5 (SLC1A7), and Sulfotransferase 1C4 (SULT1C4).
When syncytialised BeWo cells were treated with 10 nM BPA, the most significantly upregulated
genes were: Sodium-dependent phosphate transporter 2 (SLC20A2), Probable tubulin polyglutamylase
(TTLL9), Arginyl-tRNA-protein transferase 1 (ATE1), Adhesion G protein-coupled receptor A2
(GPR124), Golgi-associated plant pathogenesis-related protein 1 (GLIPR2), Tumour necrosis factor
receptor superfamily member 6 (FAS), Multiple inositol polyphosphate phosphatase 1 (MINPP1),
Protein transport protein Sec61 subunit gamma (SEC61G), Sprouty-related EVH1 domain-containing
protein 1 (SPRED1), and Carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3).
Furthermore, we have validated the SIM2 gene, at protein level, using immunofluorescence due to
its role in placental physiology and/or development. Following 24 h of 10 nM BPA treatment in
syncytialised BeWo cells, there was a marked increase in the expression of the SIM2 encoded protein in
accordance with the microarray observations (data not shown).
Enrichment analyses using Enrichr (using the WikiPathways 2019 database) revealed that the
biological pathways most associated with differentially expressed genes in 3 nM and 10 nM BPA-treated
BeWo cells are NRF2 pathway (Table 4) and mir-124 predicted interactions with cell cycle and
differentiation, respectively (Table 5).
Table 4. Top 10 biological pathways associated with differentially expressed genes after 3 nM bisphenol
A (BPA) treatment of syncytialised BeWo cells using the WikiPathways 2019 database (Enrichr).
Index Name of BiologicalPathway p-Value Input Genes
1
nuclear factor erythroid
2-related factor 2 (NRF2)
pathway
0.00464
ATP-binding cassette, sub-family C (CFTR/MRP),
member 3 (ABCC3); gamma-glutamyltransferase
light chain 1 (GGTLC1); carbonyl reductase 1 (CBR1);
NAD(P)H dehydrogenase, quinone 1 (NQO1); solute
carrier family 6 member 15 (SLC6A15); solute carrier
family 2 member 5 (SLC2A5); glutathione
S-transferase mu 5 (GSTM5)
2 Role of Osx and miRNAsin tooth development 0.01831
HNF1 homeobox A (HNF1A);
Sp7 transcription factor (SP7)
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Table 4. Cont.
Index Name of BiologicalPathway p-Value Input Genes
3 Oxidative damage 0.01849
B-cell CLL/lymphoma 2 (BCL2); cytochrome c,
somatic (CYCS); tumor necrosis factor receptor
superfamily, member 1B (TNFRSF1B)
4 Nanomaterial-inducedapoptosis 0.03164 BCL2; CYCS
5 Nuclear receptorsmeta-pathway 0.03703
ABCC3; gamma-glutamyltransferase light chain 1
(GGTLC1); carbonyl reductase 1 (CBR1); nuclear
receptor coactivator 2 (NCOA2); NQO1;
SC6A15; DnaJ (Hsp40) homolog, subfamily C,
member 15 (DNAJC15); SLC2A5; GSTM5
6 Apoptosis modulationand signalling 0.03943
BCL2; CYCS; Bcl2 modifying factor (BMF); tumor
necrosis factor receptor superfamily, member 1B
(TNFRSF1B)
7
Photodynamic
therapy-induced
NFE2L2 (NRF2) survival
signalling
0.04431 ABCC3; NQO1
8 Gastric cancer network 2 0.07007 collagen, type IX, alpha 1(COL9A1); family withsequence similarity 91, member A1 (FAM91A1)
9 Constitutive androstanereceptor pathway 0.07406 ABCC3; NCOA2
10 Oxidative stress 0.07814 NQO1; NADPH oxidase 1 (NOX1)
Most enriched biological processes were regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolism, metabolism, and energy pathways for 3 nM BPA-treated syncytialised BeWo
cells (Figure 6A,B). The 23 genes that are involved in metabolism are: UGT2B10, CA11, HS3ST3A1,
CBR1, NQO1, CHM, AGPAT4, nMRK1, BDH2, PHKG1, GFPT1, COX11, CP, NOX1, GSTM5, RNGTT,
GGTLC1, SULT1C4, CYCS, MAN2A2, NPL, SRD5A1, and ABHD1. These genes appear to create an
extensive and diverse network (Figure 6C, Supplementary Table S3).
Table 5. Top 10 biological pathways most significantly associated with differentially expressed genes
after 10 nM bisphenol A (BPA) treatment of syncytialised BeWo cells using the WikiPathways 2019
database (Enrichr).
Index Name of Biological Pathway p-Value Input Genes
1
mir-124 predicted interactions
with cell cycle and
differentiation
0.0395 STE20-related kinase adaptorbeta (STRADB)
2
LncRNA-mediated
mechanisms of therapeutic
resistance
0.0395 hypoxia inducible factor 1,alpha subunit (HIF1A)
3 MicroRNA for targeting cancergrowth and vascularization 0.0460 HIF1A
4
HIF1A and Peroxisome
Proliferator Activated
Receptor Gamma (PPARG)
regulation of glycolysis
0.0524 HIF1A
5
TGIF disruption of SHH
signalling (Hedgehog
signaling pathway)
0.0587 TGFB-induced factorhomeobox 1 (TGIF1)
J. Clin. Med. 2020, 9, 405 14 of 24
Table 5. Cont.
Index Name of Biological Pathway p-Value Input Genes
6 Notch signalling pathway 0.0631 melanoma antigen family A,1(MAGEA1); HIF1A
7 Steroid biosynthesis 0.0650 hydroxysteroid (17-beta)dehydrogenase 4 (HSD17B4)
8 Ectoderm differentiation 0.0657
frizzled class receptor 5
(FZD5); ribosome binding
protein 1 (RRBP1); WD repeat
domain 44 (WDR44)
9 G1 to S cell cycle control 0.0686
cyclin G2 (CCNG2);
polymerase (DNA directed),
epsilon, catalytic subunit
(POLE)
10 NAD metabolism, sirtuins,and aging 0.0713 HIF1A
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Figure 6. (A) Top 10 enriched (Funrich) biological processes for 3 nM BPA-treated syncytialised 
BeWos. (B) Table of genes involved in most significant biological processes. (C) Network annotation 
of genes involved in metabolism (Genemania; Supplementary Table S4). 
In the case of syncytialised BeWos treated with 10nM BPA, the most enriched biological 
processes were transport and cAMP-mediated signalling. However, only transport involved multiple 
genes (Figure 7 A,B), which were: XPO6, SLC20A2, SEC61G, SLC25A40, WDR44, RRBP1, MIP, 
SLC6A6, FABP5, FXYD3, SCN5A, COG4, CACNA2D2 that appear to form four distinct networks 
(Figure 7C, Supplementary Table S5). 
 
Figure 7. (A)Top 10 enriched (Funrich) biological processes for 10 nM BPA-treated syncytialised 
BeWos. (B) Table of genes involved in transport and protein metabolism.: exportin 6 (XPO6), solute 
carrier family 20 member 2 (SLC20A2), Sec61 translocon gamma subunit (SEC61G), solute carrier 
family 25 member 40 (SLC25A40), WD repeat domain 44 (WDR44), ribosome binding protein 1 
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In the case of syncytialised BeWos treated with 10 nM BPA, the most enriched biological processes
were transport and cAMP-mediated signalling. Ho ever, only transport involved multiple genes
(Figure 7 A,B), which were: XPO6, SLC20A2, SEC61G, SLC25A40 WDR44, RRBP1, MIP, SLC6A6,
FABP5, XYD3, SCN5A, COG4, CACNA2D2 that appear to form four distinct networks (Figure 7C,
Supplementary Table S5).
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Figure 7. (A) Top 10 enriched (Funrich) biological processes for 10 nM BPA-treated syncytialised BeWos.
(B) Table of genes involved in transport and protein metabolism.: exportin 6 (XPO6), solute carrier
family 20 member 2 (SLC20A2), Sec61 translocon gamma subunit (SEC61G), solute carrier family
25 member 40 (SLC25A40), WD repeat domain 44 (WDR44), ribosome binding protein 1 (RRBP1),
major intrinsic protein (MIP), solute carrier family 6 member 6 (SLC6A6), fatty acid binding protein 5
(FABP5), FXYD domain containing ion transport regulator 3 (FXYD3), sodium voltage-gated channel
alpha subunit 5 (SCN5A), component of oligomeric golgi complex 4 (COG4), calcium voltage-gated
channel auxiliary subunit alpha2delta 2 (CACNA2D2), ADAM metallopeptidase domain 11 (ADAM11),
ubiquitin specific peptidase 49 (USP49), arginyltransferase 1 (ATE1), F-box protein 22 (FBXO22), SPG7,
paraplegin matrix AAA peptidase subunit (SPG7), renin (REN), peptidase, mitochondrial processing
alpha subunit (PMPCA), ribosomal protein L27a (RPL27A), F-box protein 22 (FBXO22). (C) Network
annotation of genes involved in metabolism (Genemania).
4. Discussion
In this study, we investigated the effect of BPA using human placental cells, an in vitro model, in
terms of impact on cell number and activation of key kinases in a trophoblast model in vitro. We also
expanded on these observations by using whole-genome microarray analyses to study the effects of
various concentrations of BPA in nonsyncytialised and syncytialised BeWo cells.
In our studies, BPA (3 nM) significantly increased BeWo cell number, which is in line with both
in vivo and in vitro studies showing that low levels of BPA increased cell proliferation in mouse
pancreatic β-cells, rat dorsolateral prostate cells, rat bile duct cells, mouse spermatogonial cells, and
OVCAR3 cells via different mechanisms and in a concentration-dependent manner [46–50]. For example,
proliferation of ovarian cancer cell line OVCA3 was significantly increased when treated with 10−9 M
but not 10−7 M BPA [51]. Proliferation of rat prostate epithelial cells was also significantly increased
after treatment with 0.1 and 1 nM BPA, as opposed to showing decreased proliferation at 10–1000 nM
of BPA [47]. The biphasic effect of BPA has also been documented in rodent models in vivo, as well as
in the BeWo cell line despite using supra-physiological concentrations [43,48,52,53]. Furthermore, our
data corroborate a study showing that BeWo cells treated with BPA during stress-induced conditions
led to a consistent and significant increase in cell viability and a reduction in apoptosis [50]. In another
study in the same in vitro model, BPA induced cell proliferation at 1 µM and decreased the proliferation
rate of BeWos at 1000 µM [51]. In a more recent study, however, treatment of BeWo cells with BPA for
72 h did not affect either the proliferation or the metabolic activity [54]. However, none of these studies
J. Clin. Med. 2020, 9, 405 16 of 24
have provided further evidence of how BPA exerts its effects in this model. Previous studies have
indicated that BPA can activate both nuclear (ERα and ERβ) and membrane (GPR30) ERs [8,10,55,56].
In this case, the proliferative effects of BPA are attributed to the activation of GPR30 rather than ERα
and ERβ, since G15 (a GPR30 antagonist) but not ICI 182,780 (a pure ER antagonist) inhibited cell
proliferation. These data are in direct agreement with a study in testicular seminoma cells, where a
very similar effect was observed [57], where BPA acted in a nongenomic manner. Moreover, a number
of studies have also reported that BPA can induce signalling cascades via GPR30 [58,59].
BPA can affect the phosphorylation status of numerous kinases, an effect that appears to be organ-
or cell-specific. For example, both phospho-AKT and phospho-ERK1/2 have been induced by BPA in
rat mammary glands [34]. On the other hand, phospho-AKT has been shown to be downregulated
after BPA treatment in rat sertoli cells [51] and rat hippocampi [60]. In this study, we demonstrated that
BPA can induce phosphorylation of p38 and AKT, but not ERK1/2 in BeWo cells. There was a notable
decrease in cell number when both AKT and MAPK inhibitors were used, in cotreatment with BPA. In
the case of the PI3K inhibitor LY294002 (LY), it is difficult to interpret the data since treatment of BeWo
cells alone reduced cell number as well. However, it is worth mentioning that a similar treatment with
LY resulted in increased cell fusion of BeWo cells [61]. Events that drive cell fusion will undoubtedly
slow down the rate of cell growth as we have previously documented when we treated BeWo cells
with forskolin [62]. Interestingly, in the same study by Vatish et al., wortmannin—a different PI3K
inhibitor—did not alter the fusigenic capacity of BeWo cells, suggesting that LY might affect different
pathways as well. Future studies should use a wider repertoire of intracellular signalling inhibitors to
dissect these responses further.
Nonbiased microarray analyses of nonsyncytialised BeWo cells revealed some interesting targets.
It should be noted that these data are novel, since, to the best of our knowledge, no other study
has shown a comprehensive map of gene changes at placental level in vitro. When we compared
our findings to published transcriptomic research, there was no overlap of BPA-regulated genes in
endometrial or ovarian cells, suggesting that the changes observed in this study are cell-specific [63,64].
One of the most significantly upregulated genes in both 3 nM and 10 nM nonsyncytialised BeWo
cells was caveolin-1 (CAV1). CAV1 is a protein that is found in caveolae, which are 50–100 nM
wide invaginations of the cell lipid bilayer. The function of CAV1 in the placenta has not been fully
elucidated, but it has been implicated in the transport of lipids, glucose homeostasis control, regulation
of cell signalling, and membrane trafficking [65–70]. CAV1 is also involved in the palmitoylation of
ERα, securing it to caveolae/lipid rafts on the cell membrane [71–74]. During pregnancy, CAV1 has
been associated with glucose and fatty acid transport in the placenta by inducing AMPK and reducing
the GLUT1 signalling pathway and reversing macrosomia due to gestational diabetes (GD) [74].
Furthermore, CAV1 has been implicated in the mechanism of oedema in preeclampsia (PE) following
hypoxia of trophoblasts through the HMGB1/TLR4/CAV-1 pathway [75].
Another one of the most significantly upregulated genes, but not in the top 10, after treatment
with 3 nM BPA was placenta-specific 1 (PLAC1). PLAC1 has been implicated in placentomegaly in
mice [76], a condition which has implications in various disorders such as placental mesenchymal
dysplasia [77]. Since PLAC1 upregulation induces phospho-AKT [78–80], this might be a potential
mechanism at placental level that can drive upregulation of phospho-AKT and, thus, potentially
promote cell proliferation. Arguably this is a limitation in the study (i.e., to provide definitive proof
of the involvement of this gene in AKT phosphorylation in this cellular model). Future studies
overexpressing or silencing PLAC1 followed by assessment of the phosphorylation status of key
kinases should provide a novel insight.
Another upregulated gene after BPA treatment was leptin. It is well documented that placental
leptin is modulated by numerous hormones and cytokines [81,82]. Leptin is involved in the implantation
process of the embryo by increasing trophoblast matrix metalloproteinase expression, allowing for
better cell invasion [83–85]. Leptin has also been implicated in many pathologies, and there is a
correlation of maternal plasma leptin levels and the development of GD [86–90]. For example, leptin
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levels were found raised in the GD group of pregnant women, even when adjusting for confounders [86].
Higher serum leptin levels in pregnant women with PE have also been documented [91,92], and there
is an association between higher leptin expression and intrauterine growth restriction (IUGR) [93,94].
To date, a few studies have shown a relationship between BPA and leptin. For example, BPA associated
positively with adiponectin and leptin, but negatively with ghrelin, following adjustments for sex,
height, fat mass, lean mass, smoking, alcohol consumption, physical activity, energy intake, and
educational levels in 890 elderly men and women [95]. Moreover, in 3T3-L1 adipocytes differentiated
in the presence of physiological concentrations of BPA, there was an increase in the expression of leptin,
IL-6, and interferon-γ [96].
Placenta-specific protein 8 (PLAC8) was also a significantly upregulated gene in both 3 nM and
10 nM BPA-treated nonsyncytialised BeWo. PLAC8 is expressed on the feto-maternal interface, where
it plays a role in promoting trophoblast invasion and migration and is significantly upregulated
under hypoxic conditions and in PE placentae [97]. PLAC8 is implicated in diseases such as obesity,
type 2 diabetes, and GD [98]. PLAC8 was found to be highly expressed in neonatal cells exposed to
GD and expression of PLAC8 was correlated with maternal hyperglycemia [99]. PLAC8 also plays
a role in adipogenesis, brown fat differentiation, and body weight control by controlling C/EBPβ
expression [100,101]. In addition, overexpression of PLAC8 leads to increased growth, resistance to
apoptosis, and higher levels of phosphorylated Akt1 in fibroblasts [102].
The targets in both 3 nM and 10 nM BPA-treated syncytialised BeWo cells were different, indicative
of the syncytialisation process and the changes in terms of the endocrine/signalling milieu or the
activation of the cAMP/PKA/CEB pathway. GHRH was the most upregulated gene in 3 nM treated
cells. Although the expression of GHRH in the human placenta is documented, its exact role is still
poorly investigated [103], with its levels being elevated in the third trimester. In a more recent study in
another placental in vitro model (JEG-3 cells), inhibition of GHRH-R by a GHRH antagonist reduced
cell viability and induced apoptosis through inactivation of Akt [104]. It will be interesting to repeat
the experiment in syncytialised BeWo cells in order to gain a better understanding of whether this
hormone alters Akt phosphorylation.
Slc11a1 (solute carrier family 11 member 1), the gene that encodes for the Natural
resistance-associated macrophage protein 1, is upregulated in BPA-treated syncytialised BeWo cells
and plays a role in host innate immunity. This represents a divalent cation transporter which is
expressed primarily by macrophages and neutrophils and is essential for controlling infections by
intracellular pathogens, with previous studies showing its expression in the syncytiotrophoblast of
the human placenta at multiple gestational ages [105]. Moreover, the Single-Minded 2 (SIM2) gene
was significantly upregulated. This, as a basic helix–loop–helix (bHLH) protein, belongs to a group
of transcription factors that regulates several downstream genes involved in developmental and
neurological pathways [106], playing a role in proliferation and in embryo development [107].
Regarding the role of FABP5 (Fatty-Acid-Binding Protein 5), the only gene that was common
between the two treatments, very little is known regarding its role at placental level. A single study
demonstrates that FABP5 mRNA expression was reduced in placental macrovascular endothelial cells
of obese versus lean women, but not in trophoblasts [108]. This finding underpins once again the
novelty of our microarray data. Future studies should involve silencing FABP5 to dissect further its
role in placentation.
Taken together, these findings highlight the capacity of BPA to affect the BeWo cell genome.
The most significant changes were seen in cells that appeared to be most susceptible to BPA treatment,
that is, 3 nM treated nonsyncytialised BeWo cells. These changes imply a role of BPA in influencing
the metabolism, as well as the number of placental cells, factors that could significantly affect fetal
and placental development and determine the outcome of the pregnancy itself. Insulin signalling is a
pathway which has been demonstrated to play a major role during pregnancy and in diseases, such as
GD, which can have severe effects on the fetus and pregnancy, and long-term effects on both mother
and child (e.g., fetal macrosomia, maternal PE, neonatal hyperglycemia, respiratory distress syndrome,
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and development of type 2 diabetes of the mother after pregnancy, as well as increased risk of obesity
and abnormal glucose metabolism of the offspring later in life) [109–111].
In conclusion, we provide novel evidence that BPA can potentially affect mechanisms implicated in
a number of different processes in vitro, even in low nanomolar concentrations. These in vitro findings
warrant further investigation in order to elucidate the exact impact of this EDC in fetal programming.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/2/405/s1,
Table S1: Interactions of genes involved in metabolism in 3 nM BPA-treated non-ST-BeWos, Table S2: Interactions
of genes involved in metabolism in 10 nM BPA-treated non-ST-BeWos, Table S3: Interactions of genes involved in
metabolism in 3 nM BPA-treated ST-BeWos, Table S4: Acronyms of genes involved in regulation of nucleic acid
metabolism, metabolism and energy pathways, Table S5: Interactions of genes involved in metabolism in 10 nM
BPA treated ST-BeWos.
Author Contributions: The following contributions were made: conceptualization, E.K. and E.S.; methodology,
D.G., S.-C.d.A.G., E.S., and R.P; formal analysis, S.-C.d.A.G., I.K., R.P., H.R., D.G., and E.K.; writing—original
draft preparation, I.K., H.R., D.G., and E.K.; writing—review and editing, I.K., H.R., E.S., and E.K.; visualization,
I.K. and E.K.; supervision, E.K. and E.S.; project administration, E.S. and E.K.; funding acquisition, S.-C.d.A.G.
and E.K. All authors have read and agreed to the published version of the manuscript.
Funding: Isambard PhD Scholarship, Brunel University London.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Gore, A.C.; Crews, D.; Doan, L.L.; Merrill, M.L.; Patisaul, H.; Zota, A. Introduction to Endocrine Disrupting
Chemicals (EDCs): A Guide for Public Interest Organizations and Policy-Makers. Endocr. Rev. 2014.
Available online: https://www.endocrine.org/-/media/endosociety/files/advocacy-and-outreach/important-
documents/introduction-to-endocrine-disrupting-chemicals.pdf (accessed on 31 January 2020).
2. Gore, A.C.; Chappell, V.A.; Fenton, S.E.; Flaws, J.A.; Nadal, A.; Prins, G.S.; Zoeller, R.T. EDC-2: The Endocrine
Society’s second scientific statement on endocrine-disrupting chemicals. Endocr. Rev. 2015, 36, 1–150.
[CrossRef]
3. Montes-Grajales, D.; Fennix-Agudelo, M.; Miranda-Castro, W. Occurrence of personal care products as
emerging chemicals of concern in water resources: A review. Sci. Total Environ. 2017, 595, 601–614. [CrossRef]
[PubMed]
4. Brieño-Enríquez, M.A.; Robles, P.; Camats-Tarruella, N.; García-Cruz, R.; Roig, I.; Cabero, L.; Caldés, M.G.
Human meiotic progression and recombination are affected by bisphenol A exposure during In Vitro human
oocyte development. Hum. Reprod. 2011, 26, 2807–2818. [CrossRef]
5. Koch, C.A.; Diamanti-Kandarakis, E. Introduction to endocrine disrupting chemicals—Is it time to act?
Rev. Endocr. Metab. Disord. 2015, 16, 269–270. [CrossRef] [PubMed]
6. Miodovnik, A.; Engel, S.M.; Zhu, C.; Ye, X.; Soorya, L.V.; Silva, M.J.; Wolff, M.S. Endocrine disruptors and
childhood social impairment. Neurotoxicol. Teratol. 2010, 32, 261–267. [CrossRef]
7. Rahman, M.S.; Kwon, W.S.; Lee, J.S.; Yoon, S.J.; Ryu, B.Y.; Pang, M.G. Bisphenol-A affects male fertility via
fertility-related proteins in spermatozoa. Sci. Rep. 2015, 5, 1–9. [CrossRef]
8. Snyder, R.W.; Maness, S.C.; Gaido, K.W.; Welsch, F.; Sumner, S.C.J.; Fennell, T.R. Metabolism and disposition
of Bisphenol A in female rats. Toxicol. Appl. Pharmacol. 2000, 168, 225–234. [CrossRef]
9. Watkins, D.J.; Sánchez, B.N.; Téllez-Rojo, M.M.; Lee, J.M.; Mercado-García, A.; Blank-Goldenberg, C.;
Watkins, D.J. Phthalate and Bisphenol A exposure during in utero windows of susceptibility in relation to
reproductive hormones and pubertal development in girls. Environ. Res. 2017, 159, 143–151. [CrossRef]
10. Wozniak, A.L.; Bulayeva, N.N.; Watson, C.S. Xenoestrogens at picomolar to nanomolar concentrations trigger
membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor
cells. Environ. Health Perspect. 2005, 113, 431–439. [CrossRef]
11. Yolton, K.; Xu, Y.; Strauss, D.; Altaye, M.; Calafat, A.M.; Khoury, J. Prenatal exposure to Bisphenol A and
phthalates and infant neurobehavior. Neurotoxicol. Teratol. 2011, 33, 558–566. [CrossRef] [PubMed]
12. Tyl, R.W. Abbreviated assessment of Bisphenol A toxicology literature. Semin. Fetal Neonatal Med. 2014,
19, 195–202. [CrossRef] [PubMed]
J. Clin. Med. 2020, 9, 405 19 of 24
13. Peretz, J.; Vrooman, L.; Ricke, W.A.; Hunt, P.A.; Ehrlich, S.; Hauser, R.; Flaws, J.A. Bisphenol A and
reproductive health: Update of experimental and human evidence, 2007–2013. Environ. Health Perspect. 2014,
122, 775–786. [CrossRef] [PubMed]
14. Muhamad, M.S.; Salim, M.R.; Lau, W.J.; Yusop, Z. A review on Bisphenol A occurrences, health effects
and treatment process via membrane technology for drinking water. Environ. Sci. Pollut. Res. 2016,
23, 11549–11567. [CrossRef] [PubMed]
15. Erler, C.; Novak, J. Bisphenol A exposure: Human risk and health policy background of Bisphenol A. J.
Pediatr. Nurs. 2010, 25, 400–407. [CrossRef]
16. Michałowicz, J. Bisphenol A—Sources, toxicity and biotransformation. Environ. Toxicol. Pharmacol. 2014, 37,
738–758. [CrossRef]
17. Richter, C.A.; Birnbaum, L.S.; Farabollini, F.; Newbold, R.R.; Rubin, B.S.; Talsness, C.E.; vom Saal, F.S. In Vivo
effects of Bisphenol A in laboratory rodent studies. Birth Defects Res. B Dev. Reprod. Toxicol. 2007, 24, 199–224.
[CrossRef]
18. Delfosse, V.; Grimaldi, M.; Pons, J.L.; Boulahtouf, A.; le Maire, A.; Cavailles, V.; Labesse, G.; Bourgouet, W.;
Balaguer, P. Structural and mechanistic insights inot bisphenols action provide guidelines for risk assessment
and discovery of Bisphenol A substitutes. Proc. Natl. Acad. Sci. USA 2012, 109, 14930–14935. [CrossRef]
19. Matsushima, A.; Kakuta, Y.; Teramoto, T.; Koshiba, T.; Liu, X.; Okada, H.; Tokunaga, T.; Kawabata, S.;
Kimura, M.; Shimohigashi, Y. Structural evidence for endocrine disruptor Bisphenol A binding to human
nuclear receptor ERR gamma. J. Biochem. 2007, 142, 517–524. [CrossRef]
20. Liu, X.; Matsushima, A.; Nakamura, M.; Costa, T.; Nose, T.; Shimohigashi, Y. Fine spatial assembly
for construction of the phenol-binding pocket to capture Bisphenol A in the human nuclear receptor
estrogen-related receptor γ. J. Biochem. 2012, 151, 403–415. [CrossRef]
21. Balakrishnan, B.; Henare, K.; Thorstensen, E.B.; Ponnampalam, A.P.; Mitchell, M.D. Transfer of Bisphenol A
across the human placenta. Am. J. Obstet. Ginecol. 2010, 202, 393.e1–393.e7. [CrossRef] [PubMed]
22. Schönfelder, G.; Wittfoht, W.; Hopp, H.; Talsness, C.E.; Paul, M.; Chahoud, I. Parent Bisphenol A accumulation
in the human maternal-fetal-placental unit. Environ. Health Perspect. 2002, 110, A703–A707. [CrossRef]
[PubMed]
23. Ejaredar, M.; Lee, Y.; Roberts, D.J.; Sauve, R.; Dewey, D. Bisphenol A exposure and children’s behavior: A
systematic review. J. Expo. Sci. Environ. Epidemiol. 2017, 27, 175–183. [CrossRef] [PubMed]
24. Srivastava, S.; Gupta, P.; Chandolia, A.; Alam, I. Bisphenol A: A threat to human health? J. Environ. Health
2015, 77, 20–26. [PubMed]
25. Zhang, Y.; Wei, F.; Zhang, J.; Hao, L.; Jiang, J.; Dang, L.; Jiang, L. Bisphenol A and estrogen induce proliferation
of human thyroid tumor cells via an estrogen-receptor-dependent pathway. Arch. Biochem. Biophys. 2017,
633, 29–39. [CrossRef] [PubMed]
26. Berger, R.G.; Foster, W.G.; deCatanzaro, D. Bisphenol-A exposure during the period of blastocyst implantation
alters uterine morphology and perturbs measures of estrogen and progesterone receptor expression in mice.
Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 30, 393–400. [CrossRef]
27. Huo, W.; Xia, W.; Wan, Y.; Zhang, B.; Zhou, A.; Zhang, Y.; Xu, S. Maternal urinary Bisphenol A levels and
infant low birth weight: A nested case-control study of the Health Baby Cohort in China. Environ. Int. 2015,
85, 96–103. [CrossRef]
28. Machtinger, R.; Orvieto, R. Bisphenol A, oocyte maturation, implantation, and IVF outcome: Review of
animal and human data. Reprod. BioMed Online 2014, 29, 404–410. [CrossRef]
29. Rajakumar, C.; Guan, H.; Langlois, D.; Cernea, M.; Yang, K. Bisphenol A disrupts gene expression in human
placental trophoblast cells. Birth Defects Res. B Dev. Reprod. Toxicol. 2015, 53, 39–44. [CrossRef]
30. Robins, J.C.; Marsit, C.J.; Padbury, J.F.; Sharma, S.S. Endocrine disruptors, environmental oxygen, epigenetics
and pregnancy. Front. Biosci. 2011, 3, 690–700.
31. Guida, M.; Troisi, J.; Ciccone, C.; Granozio, G.; Cosimato, C.; Sardo, A.D.S.; Di Carlo, C. Bisphenol A and
congenital developmental defects in humans. Mutat. Res. 2015, 774, 33–39. [CrossRef] [PubMed]
32. Morrissey, R.E.; George, J.D.; Price, C.J.; Tyl, R.W.; Marr, M.C.; Kimmel, C.A. The developmental toxicity of
Bisphenol A in rats and mice. Fundam. Appl. Toxicol. 1987, 8, 1–582. [CrossRef]
33. Bigsby, R.; Chapin, R.E.; Daston, G.P.; Davis, B.J.; Gorski, J.; Gray, L.E.; vom Saal, F.S. Evaluating the effects
of endocrine disruptors on endocrine function during development. Environ. Health Perspect. 1999, 107
(Suppl. 4), 613–618. [PubMed]
J. Clin. Med. 2020, 9, 405 20 of 24
34. Betancourt, A.M.; Mobley, J.A.; Russo, J.; Lamartiniere, C.A. Proteomic analysis in mammary glands of rat
offspring exposed in utero to bisphenol A. Int. J. Proteom. 2010, 73, 1241–1253. [CrossRef] [PubMed]
35. Chen, X.; Wang, Y.; Xu, F.; Wei, X.; Zhang, J.; Wang, C.; Wang, Q. The rapid effect of Bisphenol-A on long-term
potentiation in hippocampus involves estrogen receptors and ERK activation. J. Neural Transplant. Plast.
2017, 2017. [CrossRef] [PubMed]
36. Gonçalves, R.; Zanatta, A.P.; Cavalari, F.C.; do Nascimento, M.A.W.; Delalande-Lecapitaine, C.;
Bouraïma-Lelong, H.; Silva, F.R.M.B. Acute effect of Bisphenol A: Signaling pathways on calcium influx in
immature rat testes. Birth Defects Res. B Dev. Reprod. Toxicol. 2018, 77, 94–102. [CrossRef]
37. Lei, B.; Peng, W.; Xu, G.; Wu, M.; Wen, Y.; Xu, J.; Wang, Y. Activation of G protein-coupled receptor 30 by
thiodiphenol promotes proliferation of estrogen receptor α-positive breast cancer cells. Chemosphere 2017,
169, 204–211. [CrossRef]
38. Wang, C.; Fu, W.; Quan, C.; Yan, M.; Liu, C.; Qi, S.; Yang, K. The role of Pten/Akt signaling pathway involved
in BPA-induced apoptosis of rat Sertoli cells. Res. J. Environ. Toxicol. 2015, 30, 793–802. [CrossRef]
39. Orendi, K.; Gauster, M.; Moser, G.; Meiri, H.; Huppertz, B. The choriocarcinoma cell line BeWo: Syncytial
fusion and expression of syncytium-specific proteins. Reproduction 2010, 140, 759–766. [CrossRef]
40. Pattillo, R.A.; Gey, G.O. The establishment trophoblastic of a cell line of human hormone-synthesizing
trophoblastic cells In Vitro. Cancer Res. 1968, 28, 1231–1236.
41. Wice, B.; Menton, D.; Geuze, H.; Schwartz, A.L. Modulators of cyclic AMP metabolism induce
syncytiotrophoblast formation in vitro. Exp. Cell Res. 1990, 186, 306–316. [CrossRef]
42. Pathan, M.; Keerthikumar, S.; Chisanga, D.; Alessandro, R.; Ang, C.-S.; Askenase, P.; Mathivanan, S. A novel
community driven software for functional enrichment analysis of extracellular vesicles data. J. Extracell.
Vesicles 2017, 6, 1321455. [CrossRef] [PubMed]
43. Chen, E.Y.; Tan, C.M.; Kou, Y.; Duan, Q.; Wang, Z.; Meirelles, G.; Ma’ayan, A. Enrichr: Interactive and
collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013, 14, 128. [CrossRef] [PubMed]
44. Chudasama, D.; Bo, V.; Hall, M.; Anikin, V.; Jeyaneethi, J.; Gregory, J.; Karteris, E. Identification of cancer
biomarkers of prognostic value using specific gene regulatory networks (GRN): A novel role of RAD51AP1
for ovarian and lung cancers. Carcinogenesis 2018, 39, 407–417. [CrossRef] [PubMed]
45. Rebut-Bonneton, C.; Boutemy-Roulier, S.; Evain-Brion, D. Modulation of pp60c-src activity and cellular
localization during differentiation of human trophoblast cells in culture. J. Cell Sci. 1993, 105 Pt 3, 629–636.
46. García-Arévalo, M.; Alonso-Magdalena, P.; Servitja, J.-M.; Boronat-Belda, T.; Merino, B.; Villar-Pazos, S.;
Nadal, A. Maternal exposure to Bisphenol-A during pregnancy increases pancreatic β-Cell growth during
early life in male mice offspring. Endocrinology 2016, 157, 4158–4171. [CrossRef]
47. Huang, D.; Wu, J.; Su, X.; Yan, H.; Sun, Z. Effects of low dose of Bisphenol A on the proliferation and
mechanism of primary cultured prostate epithelial cells in rodents. Oncol. Lett. 2017, 14, 2635–2642.
[CrossRef]
48. Jeong, J.S.; Nam, K.T.; Lee, B.; Pamungkas, A.D.; Song, D.; Kim, M.; Lim, K.-M. Low-Dose Bisphenol A
increases bile duct proliferation in juvenile rats: A possible evidence for risk of liver cancer in the exposed
population? Biomol. Ther. (Seoul) 2017, 25, 545–552. [CrossRef]
49. Sheng, Z.-G.; Huang, W.; Liu, Y.-X.; Zhu, B.-Z. Bisphenol A at a low concentration boosts mouse
spermatogonial cell proliferation by inducing the G protein-coupled receptor 30 expression. Toxicol.
Appl. Pharmacol. 2013, 267, 88–94. [CrossRef]
50. Shi, X.-Y.; Wang, Z.; Liu, L.; Feng, L.-M.; Li, N.; Liu, S.; Gao, H. Low concentrations of Bisphenol A promote
human ovarian cancer cell proliferation and glycolysis-based metabolism through the estrogen receptor-α
pathway. Chemosphere 2017, 185, 361–367. [CrossRef]
51. Ponniah, M.; Billett, E.E.; De Girolamo, L.A. Bisphenol A increases BeWo trophoblast survival in stress-induced
paradigms through regulation of oxidative stress and apoptosis. Chem. Res. Toxicol. 2015, 28, 1693–1703.
[CrossRef] [PubMed]
52. Takai, Y.; Tsutsumi, O.; Ikezuki, Y.; Hiroi, H.; Osuga, Y.; Momoeda, M.; Taketani, Y. Estrogen receptor-mediated
effects of a xenoestrogen, bisphenol A, on preimplantation mouse embryos. Biochem. Biophys. Res. Commun.
2000, 270, 918–921. [CrossRef]
J. Clin. Med. 2020, 9, 405 21 of 24
53. Wang, Z.-Y.; Lu, J.; Zhang, Y.-Z.; Zhang, M.; Liu, T.; Qu, X.-L. Effect of Bisphenol A on invasion ability of
human trophoblastic cell line BeWo. Int. J. Clin. Exp. Pathol. 2015, 8, 14355–14364. [PubMed]
54. Narciso, L.; Letta, F.; Romagnoli, R.; Paulesu, L.; Mantovani, A.; Tait, S. Effects of Bisphenol A on endogenous
retroviral envelopes expression and trophoblast fusion in BeWo cells. Reprod. Toxicol. 2019, 89, 35–44.
[CrossRef]
55. Welshons, W.V.; Nagel, S.C.; Vom Saal, F.S. Large effects from small exposures. III. Endocrine mechanisms
mediating effects of bisphenol A at levels of human exposure. Endocrinology 2006, 147, 56–69. [CrossRef]
[PubMed]
56. Welshons, W.V.; Thayer, K.A.; Judy, B.M.; Taylor, J.A.; Curran, E.M.; vom Saal, F.S. Large effects from small
exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ. Health
Perspect. 2003, 111, 994–1006. [CrossRef] [PubMed]
57. Chevalier, N.; Bouskine, A.; Fenichel, P. Bisphenol A promotes testicular seminoma cell proliferation through
GPER/GPR30. Int. J. Cancer 2012, 130, 241–242. [CrossRef] [PubMed]
58. Cimmino, I.; Oriente, F.; D’Esposito, V.; Liguoro, D.; Liguoro, P.; Ambrosio, M.R.; Cabaro, S.; D’Andrea, F.;
Beguinot, F.; Formisano, P.; et al. Low-Dose Bisphenol A regulates inflammatory cytokines through GPR30
in mammary adipose cells. J. Mol. Endocrinol. 2019, 63, 273–283. [CrossRef]
59. Herz, C.; Tran, H.T.T.; Schlotz, N.; Michels, K.; Lamy, E. Low-Dose levels of Bisphenol A inhibit telomerase
via ER/GPR30-ERK signalling, impar DNA integrity and reduce cell proliferation in primary PBMC. Sci. Rep.
2017, 7, 16631. [CrossRef]
60. Wang, C.; Li, Z.; Han, H.; Luo, G.; Zhou, B.; Wang, S.; Wang, J. Impairment of object recognition memory by
maternal Bisphenol A exposure is associated with inhibition of Akt and ERK/CREB/BDNF pathway in the
male offspring hippocampus. Toxicology 2016, 341–343, 56–64. [CrossRef]
61. Vatish, M.; Tesfa, L.; Grammatopoulos, D.; Yamada, E.; Bastie, C.C.; Pessin, J.E. Inhibition of Akt activity and
calcium channel function coordinately drive cell-cell fusion in the BeWo choreocarcinoma placental cell line.
PLoS ONE 2012, 7, e29353. [CrossRef]
62. Zachariades, E.; Foster, H.; Goumenou, A.; Thomas, P.; Rand-Weaver, M.; Karteris, E. Expression of membrane
and nuclear progesterone receptors in two human placental choriocarcinoma cell lines (JEG-3 and BeWo):
Effects of syncytialization. Int. J. Mol. Med. 2011, 27, 767–774.
63. Chou, W.C.; Lee, P.H.; Tan, Y.Y.; Lin, H.C.; Yang, C.W.; Chen, K.H.; Chuang, C.Y. An integrative transcriptomic
analysis reveals Bisphenol A exposure-induced dysregulation of microRNA expression in human endometrial
cells. Toxicol. In Vitro 2017, 41, 133–142. [CrossRef] [PubMed]
64. Hui, L.; Li, H.; Lu, G.; Chen, Z.; Sun, W.; Shi, Y.; Fu, Z.; Huang, B.; Zhu, X.; Lu, W.; et al. Low dose of
Bisphenol A modulates ovarian cancer gene expression profile and promotes epithelial to mesenchymal
transition via canonical wnt pathway. Toxicol. Sci. 2018, 164, 527–538. [CrossRef] [PubMed]
65. Asterholm, I.W.; Mundy, D.I.; Weng, J.; Anderson, R.G.W.; Scherer, P.E. Altered mitochondrial function and
metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 2012, 15, 171–185. [PubMed]
66. Ding, L.; Zeng, Q.; Wu, J.; Li, D.; Wang, H.; Lu, W.; Xu, G. Caveolin-1 regulates oxidative stress-induced
senescence in nucleus pulposus cells primarily via the p53/p21 signaling pathway In Vitro. Mol. Med. Rep.
2017, 16, 9521–9527. [CrossRef] [PubMed]
67. Fernández-Rojo, M.A.; Gongora, M.; Fitzsimmons, R.L.; Martel, N.; Martin, S.D.; Nixon, S.J.; Parton, R.G.
Caveolin-1 is necessary for hepatic oxidative lipid metabolism: Evidence for crosstalk between caveolin-1
and bile acid signaling. Cell Rep. 2013, 4, 238–247. [CrossRef]
68. Li, M.; Chen, D.; Huang, H.; Wang, J.; Wan, X.; Xu, C.; Li, Y. Caveolin1 protects against diet induced hepatic
lipid accumulation in mice. PLoS ONE 2017, 12, e0178748. [CrossRef]
69. Parton, R.G.; Simons, K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 2007, 8, 185–194. [CrossRef]
70. Smart, E.J.; Graf, G.A.; McNiven, M.A.; Sessa, W.C.; Engelman, J.A.; Scherer, P.E.; Lisanti, M.P. Caveolins,
liquid-ordered domains, and signal transduction. Mol. Cell Biol. 1999, 19, 7289–7304. [CrossRef]
71. Adlanmerini, M.; Solinhac, R.; Abot, A.; Fabre, A.; Raymond-Letron, I.; Guihot, A.-L.; Lenfant, F. Mutation
of the palmitoylation site of estrogen receptor α In Vivo reveals tissue-specific roles for membrane versus
nuclear actions. Proc. Natl. Acad. Sci. USA 2014, 111, E283–E290. [CrossRef]
J. Clin. Med. 2020, 9, 405 22 of 24
72. Chambliss, K.L.; Yuhanna, I.S.; Mineo, C.; Liu, P.; German, Z.; Sherman, T.S.; Shaul, P.W. Estrogen receptor
alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae.
Circ. Res. 2000, 87, E44–E52. [CrossRef] [PubMed]
73. Levin, E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005, 19, 1951–1959.
[CrossRef]
74. Yao, G.; Zhang, Y.; Wang, D.; Yang, R.; Sang, H.; Han, L.; Shang, Z. GDM-Induced macrosomia is reversed
by Cav-1 via AMPK-Mediated fatty acid transport and GLUT1-Mediated glucose transport in placenta.
PLoS ONE 2017, 12, e0170490. [CrossRef] [PubMed]
75. Jiang, R.; Cai, J.; Zhu, Z.; Chen, D.; Wang, J.; Wang, Q.; Chen, A.F. Hypoxic trophoblast HMGB1 induces
endothelial cell hyperpermeability via the TRL-4/caveolin-1 pathway. J. Immunol. 2014, 193, 5000–5012.
[CrossRef] [PubMed]
76. Suemizu, H.; Aiba, K.; Yoshikawa, T.; Sharov, A.A.; Shimozawa, N.; Tamaoki, N.; Ko, M.S. Expression
profiling of placentomegaly associated with nuclear transplantation of mouse ES cells. Dev. Biol. 2003,
253, 36–53. [CrossRef]
77. Pawoo, N.; Heller, D.S. Placental mesenchymal dysplasia. Arch. Pathol. Lab. Med. 2014, 138, 1247–1249.
[CrossRef] [PubMed]
78. Koslowski, M.; Türeci, O.; Biesterfeld, S.; Seitz, G.; Huber, C.; Sahin, U. Selective activation of
trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform
2. J. Biol. Chem. 2009, 284, 28607–28615. [CrossRef] [PubMed]
79. Wagner, M.; Koslowski, M.; Paret, C.; Schmidt, M.; Türeci, O.; Sahin, U. NCOA3 is a selective co-activator
of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer 2013,
13, 570. [CrossRef]
80. Yang, L.; Zha, T.-Q.; He, X.; Chen, L.; Zhu, Q.; Wu, W.-B.; Lu, K.-H. Placenta-Specific protein 1 promotes cell
proliferation and invasion in non-small cell lung cancer. Oncol. Rep. 2018, 39, 53–60. [CrossRef]
81. Chardonnens, D.; Cameo, P.; Aubert, M.L.; Pralong, F.P.; Islami, D.; Campana, A.; Bischof, P. Modulation of
human cytotrophoblastic leptin secretion by interleukin-1alpha and 17beta-oestradiol and its effect on HCG
secretion. Mol. Hum. Reprod. 1999, 5, 1077–1082. [CrossRef] [PubMed]
82. López Fontana, C.M.; Maselli, M.E.; Pérez Elizalde, R.F.; Di Milta Mónaco, N.A.; Uvilla Recupero, A.L.;
López Laur, J.D. Leptin increases prostate cancer aggressiveness. J. Physiol. Biochem. 2011, 67, 531–538.
[CrossRef] [PubMed]
83. Castellucci, M.; De Matteis, R.; Meisser, A.; Cancello, R.; Monsurrò, V.; Islami, D.; Bischof, P. Leptin modulates
extracellular matrix molecules and metalloproteinases: Possible implications for trophoblast invasion.
Mol. Hum. Reprod. 2000, 6, 951–958. [CrossRef] [PubMed]
84. Chrelias, G.; Makris, G.M.; Papanota, A.M.; Spathis, A.; Salamalekis, G.; Sergentanis, T.N.; Chrelias, C. Serum
inhibin and leptin: Risk factors for pre-eclampsia? Clin. Chim. Acta. 2016, 463, 84–87. [CrossRef] [PubMed]
85. Gambino, Y.P.; Maymó, J.L.; Pérez Pérez, A.; Calvo, J.C.; Sánchez-Margalet, V.; Varone, C.L. Elsevier
trophoblast research award lecture: Molecular mechanisms underlying estrogen functions in trophoblastic
cells—Focus on leptin expression. Placenta 2012, 33, S63–S70. [CrossRef] [PubMed]
86. Fatima, S.S.; Alam, F.; Chaudhry, B.; Khan, T.A. Elevated levels of chemerin, leptin, and interleukin-18 in
gestational diabetes mellitus. J. Matern. Fetal Neonatal Med. 2017, 30, 1023–1028. [CrossRef]
87. Jeon, E.J.; Hong, S.Y.; Lee, J.H. Adipokines and insulin resistance according to characteristics of pregnant
women with gestational diabetes mellitus. Diabetes Metab. 2017, 41, 457–465. [CrossRef]
88. Lobo, T.F.; Torloni, M.R.; Mattar, R.; Nakamura, M.U.; Alexandre, S.M.; Daher, S. Adipokine levels in
overweight women with early-onset gestational diabetes mellitus. J. Endocrinol. Invest. 2018, 42, 149–156.
[CrossRef]
89. Popova, P.; Vasilyeva, L.; Tkachuck, A.; Puzanov, M.; Golovkin, A.; Bolotko, Y.; Grineva, E. A randomised,
controlled study of different glycaemic targets during gestational diabetes treatment: Effect on the level of
adipokines in cord blood and ANGPTL4. Int. J. Endocrinol. 2018, 2018, 6481658. [CrossRef]
90. Sweeting, A.N.; Wong, J.; Appelblom, H.; Ross, G.P.; Kouru, H.; Williams, P.F.; Hyett, J.A. A novel early
pregnancy risk prediction model for gestational diabetes mellitus. Fetal Diagn. Ther. 2019, 45, 76–84.
[CrossRef]
J. Clin. Med. 2020, 9, 405 23 of 24
91. El Shahat, A.M.; Ahmed, A.B.; Ahmed, M.R.; Mohamed, H.S. Maternal serum leptin as a marker of
preeclampsia. Arch. Gynecol. Obstet. 2013, 288, 1317–1322. [CrossRef] [PubMed]
92. Güngör, Z.B.; Ekmekçi, H.; Tüten, A.; Toprak, S.; Ayaz, G.; Çalışkan, O.; Balcı Ekmekçi, Ö. Is there any
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